AVOPEF Drug Patent Profile
Which patents cover Avopef, and what generic alternatives are available?
Avopef is a drug marketed by Avyxa Holdings and is included in one NDA.
The generic ingredient in AVOPEF is etoposide. There is one drug master file entry for this compound. Nine suppliers are listed for this compound. Additional details are available on the etoposide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Avopef
A generic version of AVOPEF was approved as etoposide by HIKMA on July 17th, 1995.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AVOPEF?
- What are the global sales for AVOPEF?
- What is Average Wholesale Price for AVOPEF?
Summary for AVOPEF
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 6,465 |
| What excipients (inactive ingredients) are in AVOPEF? | AVOPEF excipients list |
| DailyMed Link: | AVOPEF at DailyMed |
Pharmacology for AVOPEF
| Drug Class | Topoisomerase Inhibitor |
| Mechanism of Action | Topoisomerase Inhibitors |
US Patents and Regulatory Information for AVOPEF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avyxa Holdings | AVOPEF | etoposide | SOLUTION;INTRAVENOUS | 220200-001 | Feb 13, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Avyxa Holdings | AVOPEF | etoposide | SOLUTION;INTRAVENOUS | 220200-002 | Jun 24, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
